CEL-BSA Control Native Protein
CEL-BSA Control
Synonyms
CEL-BSA Control; CEL-BSA Control native protein
Concentration
1mg/ml (varies by lot)
Methods
Dilute the CEL-BSA with SDS-PAGE reducing sample buffer to 1.0-10 ug/mL and boil for 5 minutes. Load 10 uL per lane for western blot analysis of CEL protein adducts.
Quantity
100 uL of 1.0 mg/mL CEL-BSA in 1X PBS.
Preparation and Storage
-20 degree C. Shelf Life: 1 year from date of receipt under proper storage conditions; aliquot to avoid multiple freeze thaw cycles
Related Product Information for CEL-BSA Control native protein
• Provided at 1 mg/mL in 1X PBS
The non-enzymatic reaction of reducing carbohydrates with lysine side chains and N-terminal amino groups of macromolecules (proteins, phospholipids and nucleic acids) is called the Maillard reaction or glycation. The products of this process, termed advanced glycation end products (AGEs), adversely affect the functional properties of proteins, lipids and DNA. Tissue levels of AGE increase with age and the formation of AGEs is predominantly endogenous, though these products can also be derived from exogenous sources such as food and tobacco smoke. AGE modification of proteins can contribute to the pathophysiology of aging and long-term complications of diabetes, atherosclerosis and renal failure. AGEs also interact with a variety of cell-surface AGE-binding receptors (RAGE), leading either to their endocytosis and degradation or to cellular activation and pro-oxidant or pro-inflammatory events.
Although several AGE structures have been reported, it was demonstrated that Nepsilon-(carboxymethyl) lysine (CML) and Nepsilon-(carboxyethyl) lysine (CEL) are the major antigenic AGE structures. Next to glucose, reactive di-carbonyl compounds such as methylglyoxal are major precursors in the formation of cellular and extracellular AGEs. Methylglyoxal reacts with lysine residues to form CEL. CEL concentration is increased in patients who have diabetes with complications.
The non-enzymatic reaction of reducing carbohydrates with lysine side chains and N-terminal amino groups of macromolecules (proteins, phospholipids and nucleic acids) is called the Maillard reaction or glycation. The products of this process, termed advanced glycation end products (AGEs), adversely affect the functional properties of proteins, lipids and DNA. Tissue levels of AGE increase with age and the formation of AGEs is predominantly endogenous, though these products can also be derived from exogenous sources such as food and tobacco smoke. AGE modification of proteins can contribute to the pathophysiology of aging and long-term complications of diabetes, atherosclerosis and renal failure. AGEs also interact with a variety of cell-surface AGE-binding receptors (RAGE), leading either to their endocytosis and degradation or to cellular activation and pro-oxidant or pro-inflammatory events.
Although several AGE structures have been reported, it was demonstrated that Nepsilon-(carboxymethyl) lysine (CML) and Nepsilon-(carboxyethyl) lysine (CEL) are the major antigenic AGE structures. Next to glucose, reactive di-carbonyl compounds such as methylglyoxal are major precursors in the formation of cellular and extracellular AGEs. Methylglyoxal reacts with lysine residues to form CEL. CEL concentration is increased in patients who have diabetes with complications.
Product Categories/Family for CEL-BSA Control native protein
References
1. Monnier, V., and Cerami, A. (1981) Science 211, 491-493.
2. Ahmed M.U., Thorpe S.R., Baynes J.W (1986) J. Biol. Chem. 261, 4889-4894.
3. Reddy S., Bichler J., Wells-Knecht K.J., Thorpe S.R., Baynes J.W (1995) Biochemistry 34, 10872-10878.
4. Dunn, J. A., Patrick, J. S., Thorpe, S. R., and Baynes, J. W. (1989) Biochemistry 28, 9464-9468.
5. Ahmed, M. U., Brinkmann Frye, E., Degenhardt, T. P., Thorpe, S. R., and Baynes, J. W. (1997) Biochem. J. 324, 565-570.
6. Sell, D. R., and Monnier, V. M. (1989) J. Biol. Chem. 264, 21597-21602.
7. Onorato, J., Jenkins, A., Thorpe, S., and Baynes, J. (2000) J. Biol. Chem. 275, 21177-21184.
8. Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel P, Stahl P (2004) Diabetologia 47, 1376 1379.
9. Koito W, Araki T, Horiuchi S, Nagai R (2004) J. Biochem. 136, 831-837.
10. Nagai R., Fujiwara Y., Mera K., Yamagata K., Sakashita N., Takeya M. (2008) J. Immunol. Methods 332, 112-120.
2. Ahmed M.U., Thorpe S.R., Baynes J.W (1986) J. Biol. Chem. 261, 4889-4894.
3. Reddy S., Bichler J., Wells-Knecht K.J., Thorpe S.R., Baynes J.W (1995) Biochemistry 34, 10872-10878.
4. Dunn, J. A., Patrick, J. S., Thorpe, S. R., and Baynes, J. W. (1989) Biochemistry 28, 9464-9468.
5. Ahmed, M. U., Brinkmann Frye, E., Degenhardt, T. P., Thorpe, S. R., and Baynes, J. W. (1997) Biochem. J. 324, 565-570.
6. Sell, D. R., and Monnier, V. M. (1989) J. Biol. Chem. 264, 21597-21602.
7. Onorato, J., Jenkins, A., Thorpe, S., and Baynes, J. (2000) J. Biol. Chem. 275, 21177-21184.
8. Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel P, Stahl P (2004) Diabetologia 47, 1376 1379.
9. Koito W, Araki T, Horiuchi S, Nagai R (2004) J. Biochem. 136, 831-837.
10. Nagai R., Fujiwara Y., Mera K., Yamagata K., Sakashita N., Takeya M. (2008) J. Immunol. Methods 332, 112-120.
Similar Products
Product Notes
The CEL-BSA Control (Catalog #AAA168667) is a Native Protein and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "CEL-BSA Control, Native Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
